Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease

The main purpose of this study is to define the molecular profile of selected solid tumors. From each participants will be collected biological materials for molecular analysis, including saliva, blood and vital tumor tissue derived form surgical or biopsy procedures. Whereas possible, vital tumor specimens will be inoculated and propagated in immunocompromised NOD/SCID mice to study the genetic correlations between genetic status and response to target drugs.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale Regionale Umberto Parini, Aosta, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with at least one of the following selected solid tumors:

Colorectal Cancer (primary or with synchronous/metachronous liver metastases)
Prostate Cancer
Head & Neck Tumors
Gastric Cancer
Glioblastoma
Breast Cancer
Hepatocarcinoma
Biliary Tract Carcinoma
Lung Cancer (primary)
Rare Tumors (incidence ≤ 5x10-6)
Metastatic Sarcoma
Metastatic Melanoma

Exclusion criteria

Treatment and study plan

Primary outcomes

number of patient correctly sampled

Time frame: through study completion, an average of five years

number of patients with biological samples idoneous for molecular profiling testing (nucleic acid extraction, protein) over all recruited patients.

Secondary outcomes

number of patients with detected genetic alterations that respond to treatments assigned by physician.

Time frame: through study completion, an average of five years

Sponsors and collaborators

Lead sponsor

Fondazione del Piemonte per l'Oncologia

Other

Registry information

Official study title

Non-interventional Study for the Determination of Molecular Resistance Profiling to Targeted Therapies in Patients With Neoplastic Disease

Acronym: PROFILING

Important dates

Study start: 2011
Primary completion: 2026
Study completion: 2026
First posted: Nov 20, 2017
Registry last updated: Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting